JPM 2023 吉利德.pdf

1、Gilead in 2023 and BeyondJ.P.Mor ga n H ea lt h ca r e C on fer en ce9 Ja n u a r y 2 0 2 3Forward-Looking StatementsStatements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.Gi

2、leadcautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially.These risks and uncertainties include thoserelating to:the impact of the COVID-19 pandemic on Gileads business,financial condition and results of o

3、perations;the development,manufacturing and distribution of Veklury as atreatment for COVID-19,including the uncertainty of the amount and timing of future Veklury sales,and Gileads ability to effectively manage the global supply and distribution of Veklury;Gileads ability to achieve its anticipated

4、 full year 2022 financial results,including as a result of potential adverse revenue impacts from COVID-19 and potential revenues from Veklury;Gileads ability to make progress on any of its long-term ambitions or strategic priorities laid out in its corporate strategy;Gileads ability to accelerate o

5、r sustain revenues for its virology,oncology and other programs;Gileads ability to realize the potential benefits of acquisitions,collaborations or licensing arrangements;Gileads ability to initiate,progress or completeclinical trials within currently anticipated timeframes or at all,the possibility

6、 of unfavorable results from ongoing and additional clinical trials and the risk that safety and efficacy data fromclinical trials may not warrant further development of Gileads product candidates or the product candidates of Gileads strategic partners;Gileads ability to submit new drug applications